MaxCyte, Inc. Deferred Revenue (Non-Current)
MaxCyte, Inc. (MXCT) had Deferred Revenue (Non-Current) of $344.60 thousand as of 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2022-11-09
- 2022-09-30: Deferred Revenue, Noncurrent $344.60K.
- 2021-12-31: Deferred Revenue, Noncurrent $450.20K.
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2022-09-30 | $344.60K 10-Q · filed 2022-11-09 |
| 2021-12-31 | $450.20K 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |